8-K Impact 6/10 Debt Issuance

$TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

September 16, 2026 · AI-analyzed SEC filing

Teva Pharmaceutical Industries Limited, through three wholly owned Dutch finance subsidiaries, issued €1.5 billion and $3.2 billion in senior notes across five tranches on September 16, 2026. The Euro notes consist of €1.0B at 4.250% due 2033 and €500M at 4.625% due 2036. The USD notes consist of $1.2B at 5.250% due 2032, $1.0B at 5.500% due 2034, and $1.0B at 5.750% due 2037. Net proceeds will fund conditional redemptions of higher-coupon outstanding notes — including 6.750% (2028), 7.875% and 7.375% sustainability-linked notes (2029), 8.125% SLSNs (2031), and portions of 4.750% (2027) and 4.

TEVA down 2.13% since filing ($39.37 → $38.53). The modest decline likely reflects the dilutive effect of adding $4.7B-equivalent in gross debt, even though proceeds refinance higher-cost obligations. After-hours session is underway but no extended-hours trade data is available.

A ~$4.7B-equivalent refinancing that swaps 6.75%–8.125% legacy coupons for 4.25%–5.75% paper meaningfully lowers Teva's interest burden, a key lever for the heavily indebted generic-drug giant.

Teva continues its multi-year liability management strategy of swapping high-coupon legacy debt from the Actavis acquisition era for lower-rate paper, following similar refinancings in prior years.

The new notes add gross leverage before the old notes are retired, creating a temporary debt overhang. Change-of-control provisions require repurchase at 101% of principal, and customary cross-acceleration events of default could trigger if other indebtedness is accelerated.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →